Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Inclusion Criteria: * Subject must be able to provide informed consent * Subject must be 18 years of age or older * Subject must have histologically confirmed ACC by Department of Pathology at Dartmouth Hitchcock Medical Center * Subject must have inoperable disease * Subject must have received some form of systemic therapy prior to enrolling in the study Exclusion Criteria: * known severe hypersensitivity to Iressa * other co-existing malignancies diagnosed within the last five years except basal cell cancer or cervical cancer in situ * any unresolved CTC grade 2 toxicity from previous anticancer therapy (except alopecia) * absolute neutrophil count less than 1.5 x 1,000,000,000 per liter * platelets less than 20 x 1,000,000,000 per liter * severe uncontrolled systemic disease * pregnancy\\breastfeeding * women who are fertile and not willing to practice abstinence or contraception * use of phenytoin, carbamazepine, rifampicin, barbiturates, or St. John's Wort * treatment with a non-approved or investigational drug within 28 days before Day 1 of study treatment * prior use of ZD1839 (Iressa) or any other anti-EGFR therapies